A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01).

Yong Jae Lee; Myong Cheol Lim; Byoung-Gie Kim; Chel Hun Choi; Sang-Yoon Park; Tan, David S. P.; Yunjung Go; Jung-Yun Lee

Background: The optimal treatment of BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer remains unknown. Recently, there is an increase in the evidence to support the role of the combination of a poly(adenosine diphosphate-ribose) polymerase inhibitor, anti-angiogenic agents, and immunotherapy as maintenance therapy in BRCA wild-type patients with platinum-sensitive recurrence. We hypothesized that adding pembrolizumab and bevacizumab to olaparib maintenance can increase progression-free survival (PFS) in BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer. Methods: BRCA wild-type patients who received two previous courses of platinum-containing therapy, achieved complete or partial response to last treatment, and the treatment-free interval is >6 months after the penultimate platinum-based chemotherapy offered olaparib maintenance with pembrolizumab and bevacizumab. Forty-four patients will be included from 4 sites across Singapore and Korea. The primary endpoint of the study is 6-month PFS rate.

SINGAPORE; SOUTH Korea; BRCA genes; OVARIAN cancer; BEVACIZUMAB; PEMBROLIZUMAB; PROGRESSION-free survival

Journal of Gynecologic Oncology, 2021, Vol 32, Issue 2, p1

2005-0380

Academic Journal

10.3802/jgo.2021.32.e31